Toll Free: 1-888-928-9744
Published: May, 2014 | Pages:
36 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Ambit Biosciences Corporation - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Ambit Biosciences Corporation - Product Pipeline Review - 2014', provides an overview of the Ambit Biosciences Corporation's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Ambit Biosciences Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Ambit Biosciences Corporation including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Ambit Biosciences Corporation's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Ambit Biosciences Corporation's pipeline products Reasons to buy - Evaluate Ambit Biosciences Corporation's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Ambit Biosciences Corporation in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Ambit Biosciences Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Ambit Biosciences Corporation and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ambit Biosciences Corporation - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Ambit Biosciences Corporation and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Ambit Biosciences Corporation Snapshot 5 Ambit Biosciences Corporation Overview 5 Key Information 5 Key Facts 5 Ambit Biosciences Corporation - Research and Development Overview 6 Key Therapeutic Areas 6 Ambit Biosciences Corporation - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Out-Licensed Products 11 Out-Licensed Products/Combination Treatment Modalities 12 Ambit Biosciences Corporation - Pipeline Products Glance 13 Ambit Biosciences Corporation - Late Stage Pipeline Products 13 Phase III Products/Combination Treatment Modalities 13 Ambit Biosciences Corporation - Clinical Stage Pipeline Products 14 Phase II Products/Combination Treatment Modalities 14 Phase I Products/Combination Treatment Modalities 15 Ambit Biosciences Corporation - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Ambit Biosciences Corporation - Drug Profiles 17 quizartinib 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 AC-410 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 AC-430 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 AC-708 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Ambit Biosciences Corporation - Pipeline Analysis 23 Ambit Biosciences Corporation - Pipeline Products by Target 23 Ambit Biosciences Corporation - Pipeline Products by Route of Administration 24 Ambit Biosciences Corporation - Pipeline Products by Molecule Type 25 Ambit Biosciences Corporation - Pipeline Products by Mechanism of Action 26 Ambit Biosciences Corporation - Recent Pipeline Updates 27 Ambit Biosciences Corporation - Dormant Projects 32 Ambit Biosciences Corporation - Discontinued Pipeline Products 33 Discontinued Pipeline Product Profiles 33 AC-480 33 Ambit Biosciences Corporation - Locations And Subsidiaries 34 Head Office 34 Other Locations & Subsidiaries 34 Appendix 35 Methodology 35 Coverage 35 Secondary Research 35 Primary Research 35 Expert Panel Validation 35 Contact Us 36 Disclaimer 36
List of Tables Ambit Biosciences Corporation, Key Information 5 Ambit Biosciences Corporation, Key Facts 5 Ambit Biosciences Corporation - Pipeline by Indication, 2014 8 Ambit Biosciences Corporation - Pipeline by Stage of Development, 2014 9 Ambit Biosciences Corporation - Monotherapy Products in Pipeline, 2014 10 Ambit Biosciences Corporation - Out-Licensed Products in Pipeline, 2014 11 Ambit Biosciences Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2014 12 Ambit Biosciences Corporation - Phase III, 2014 13 Ambit Biosciences Corporation - Phase II, 2014 14 Ambit Biosciences Corporation - Phase I, 2014 15 Ambit Biosciences Corporation - Preclinical, 2014 16 Ambit Biosciences Corporation - Pipeline by Target, 2014 23 Ambit Biosciences Corporation - Pipeline by Route of Administration, 2014 24 Ambit Biosciences Corporation - Pipeline by Molecule Type, 2014 25 Ambit Biosciences Corporation - Pipeline Products by Mechanism of Action, 2014 26 Ambit Biosciences Corporation - Recent Pipeline Updates, 2014 27 Ambit Biosciences Corporation - Dormant Developmental Projects,2014 32 Ambit Biosciences Corporation - Discontinued Pipeline Products, 2014 33 Ambit Biosciences Corporation, Other Locations 34
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.